![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Bristol Myers Squibb’s Opdivo for Advanced Esophageal Squamous Cell Carcinoma
FDA Approves Bristol Myers Squibb’s Opdivo for Advanced Esophageal Squamous Cell Carcinoma
June 12, 2020
The FDA has approved Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma who were previously treated with fluoropyrimidine- and platinum-based chemotherapy.
The approval was based on positive results from a phase 3 study in which patients treated with Opdivo demonstrated superior overall survival compared to those given chemotherapy.
Opdivo is the first approved immunotherapy for this patient population.
Upcoming Events
-
21Oct